Product Description
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Peru | Portugal | Slovenia | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Overweight|Dyslipidemia|Insulin Resistance|Obesity|Atherosclerosis|Other|Alcoholism|Healthy Volunteers|Cocaine-Related Disorders|Obesity, Abdominal|Diabetes, Gestational|Inflammation
Phase 3: Smoking Cessation|Tobacco Use Disorder|Obesity|Metabolic Syndrome X|Other|Albuminuria|Arteriosclerosis|Carotid Stenosis|Type 2 Diabetes|Dyslipidemia|Atherosclerosis|Prediabetic State|Myocardial Ischemia|Glucose Intolerance|Coronary Artery Disease|Weight Loss|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Overweight|Myocardial Infarction|Stroke|Obesity, Abdominal|Weight Gain|Non-alcoholic Steatohepatitis|Prader-Willi Syndrome|Spinal Cord Injuries|Hepatitis, Alcoholic|Schizophrenia
Phase 2: Spinal Cord Injuries|Marijuana Abuse|Tobacco Use Disorder|Psychotic Disorders|Affective Disorders, Psychotic|Hypertension|Schizophrenia|Obesity|Alcoholic Intoxication|Polycystic Ovary Syndrome
Phase 1: Marijuana Abuse
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001522-30 | P3 |
Active, not recruiting |
Spinal Cord Injuries |
2024-09-29 |
|
| RIMOFATSCI-2 | P2 |
Not yet recruiting |
Spinal Cord Injuries |
2023-11-01 |
|
| RIMOFATSCI-1 | P2 |
Completed |
Spinal Cord Injuries |
2022-06-07 |
|
| Effec Acomplia gastric sensitivity | P4 |
Completed |
Healthy Volunteers |
2021-03-03 |